nach oben

Journal of Mammary Gland Biology and Neoplasia

Erschienen in:

01.06.2008

The Neuregulin Family of Genes and their Multiple Splice Variants in Breast Cancer

verfasst von: Nandini V. L. Hayes, William J. Gullick

Erschienen in: Journal of Mammary Gland Biology and Neoplasia | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

The neuregulin family consists of four genes, NRG1–4 which can each encode products containing a domain related to the epidermal growth factor family of ligands. Each gene is subject to complex control of transcription and to splicing of their mRNA product to give many variant proteins. These do not contain secretory sequences but some, through their transmembrane sequence, are routed via the Golgi where they are glycosylated, to the cell surface. Here they may be released by regulated proteolysis to act as soluble proteins which can interact and activate members of the EGF receptor family of receptor tyrosine kinases. Other splice variants do not encode transmembrane sequences and these are found either in the cytoplasm or, if they encode a nuclear localisation sequence, in distinct compartments in the nucleoplasm. It has been shown that the variants containing a full EGF domain can act as receptor agonists but the function of the cytoplasmic and nuclear products is unknown as yet. All four neuregulin genes are expressed and play an important role in mammary gland development. They are also expressed at elevated levels in some cases of ductal carcinoma in situ of the breast and breast cancer. They seem to be active in this setting and their presence may affect the efficacy of treatment with endocrine agents or with signal transduction inhibitors directed at the EGF receptor family members. Much remains to be learned however of their normal function and their influence on breast cancer development, progression and response to therapy.

Nur mit Berechtigung zugänglich

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–37.PubMedCrossRef

Harrison PJ, Law A. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006;60:132–40.PubMedCrossRef

Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signalling network: receptor heterodimerisation in development and cancer. EMBO J 2000;19:3159–67.PubMedCrossRef

Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, et al. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem 2005;280:8503–12.PubMedCrossRef

Uchida T, Wada K, Akamatsu T, Yonezawa M, Noguchi H, Mizoguchi A, et al. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of ErbB-4 in MKN28 gastric cancer cells. Biochem Biophys Res Commun 1999;266:593–602.PubMedCrossRef

Siegel DA, Davies P, Dobrenis K, Huang M. Tomoregulin 2 is found extensively in plaques in Alzheimer’s disease brain. J Neurochem 2006;98:34–44.PubMedCrossRef

Kinugasa Y, Ihiguro H, Tokita Y, Oohira A, Ohmoto H, Higashiyama S. Neuroglycan C, a new member of the neuregulin family. Biochem Biophys Res Commun 2004;321:1045–9.PubMedCrossRef

Stein RA, Staros JV. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evol Biol 2006;6:79.PubMedCrossRef

Falls D. Neuregulins: functions, forms and signalling strategies. Exp Cell Res 2003;284:14–30.PubMedCrossRef

10.

Higashiyama S, Horikawa M, Yamada K, Ichino N, Nakano N, Nakagawa T, et al. A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4. J Biochem 1997;122:675–80.PubMed

11.

Busfield SJ, Michnick DA, Chickering TW, Revett TL, Ma J, Woolf EA, et al. Characterisation of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus. Mol Cell Biol 1997;17:4007–14.PubMed

12.

Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, et al. Neuregulin 3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A 1997;94:9562–7.PubMedCrossRef

13.

Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, et al. Neuregulin 4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999;18:2681–9.PubMedCrossRef

14.

Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995;378:386–90.PubMedCrossRef

15.

Britto JM, Lukehurst S, Weller R, Fraser C, Qiu Y, Hertzog P, et al. Generation and characterisation of neuregulin-2-deficient mice. Mol Cell Biol 2004;24:8221–6.PubMedCrossRef

16.

Esper RM, Pankonin MS, Loeb JA. Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. Brain Res Rev 2006;51:161–75.PubMedCrossRef

17.

Iivanainen E, Paatero I, Heikkinen SM, Junttila TT, Cao R, Klint P, et al. Intra- and extracellular signalling by endothelial neuregulin-1. Exp Cell Res 2007;313:2896–909.PubMedCrossRef

18.

Wansbury O, Panchai H, James M, Parry S, Ashworth A, Howard B. Dynamic expression of ErbB pathway members during early mammary gland development. J Invest Dermatol 2008;128:1009–21.PubMedCrossRef

19.

Longart M, Liu Y, Karavanova I, Buonanno A. Neuregulin 2 is developmentally regulated and targeted to dendrites of central neurons. J Comp Neurol 2004;472:156–72.PubMedCrossRef

20.

Carraway KL, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 1997;387:512–6.PubMedCrossRef

21.

Chang H, Riese DJ, Glbert W, Stern DL, McMahan UJ. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 1997;387:509–12.PubMedCrossRef

22.

Yamada K, Ichino N, Nishii K, Sawada H, Higashiyama S, Ishiguro H, et al. Characterisation of the human NTAK gene structure and distribution of the isoforms for rat NTAK mRNA. Gene 2000;255:15–24.PubMedCrossRef

23.

Rimer M, Prieto AL, Weber AL, Colasante C, ponomareva O, Fromm L, et al. Neuregulin-2 is synthesised by motor neurons and terminal Schwann cells and activates acetylcholine receptor transcription in muscle cells expressing ErB4. Mol Cell Neurosci 2004;26:271–81.PubMedCrossRef

24.

Carteron C, Ferrer-Montiel A, Cabedo H. Characterisation of a neural-specific splicing form of the human neuregulin 3 gene involved in oligodendrocyte survival. J Cell Sci 2005;119:898–909.CrossRef

25.

Dunn M, Sinha P, Campbell R, Levinson N, Rampaul R, Bates T, et al. Co-expression of neuregulin 1, 2, 3 and 4 in human breast cancer. J Pathol 2004;203:672–80.PubMedCrossRef

26.

Hayes NVL, Blackburn E, Smart LV, Boyle M, Russell G, Frost T, et al. (2007) Identification and characterisation of novel spliced variants of NRG4 in prostate cancer. Clin Cancer Res 2007;13:3147–55.PubMedCrossRef

27.

Steinthorsdottir V, Stefansson H, Birgisdottir B, Bjornsdottir S, Fasquel AC, et al. Multiple novel transcription sites for NRG1. Gene 2004;342:97–105.PubMedCrossRef

28.

Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999;447:227–31.PubMedCrossRef

29.

Montero JC, Yuste L, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A. Mitogen-activated protein kinase-dependent and –independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem J 2002;363:211–21.PubMedCrossRef

30.

McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol. 2008;in press.

31.

Zhou B-BS, Peyton MB, He B, Liu C, Girard L, Caudler E, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006;10:39–50.PubMedCrossRef

32.

Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007;117:337–45.PubMedCrossRef

33.

Schaefer G, Fitzpatrick VD, Sliwkowski MX. G-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. Oncogene 1997;15:1385–94.PubMedCrossRef

34.

Ring HZ, Chang H, Guilbot A, Brice A, LeGuern E, Francke U. The human neuregulin-2 (NRG2) gene: cloning, mapping and evaluation as a candidate for the autosomal recessive form of Charcot–Marie–Tooth disease linked to 5q. Hum Genet 1999;104:326–32.PubMedCrossRef

35.

Nakano N, Higashiyama S, Kajihara K, Endo T, Ishiguro H, Yamada K, et al. NTAKa and b isoforms stimulate breast tumour cell growth by means of different receptor combinations. J Biochem 2000;127:925–30.PubMed

36.

Hobbs SS, Coffing SL, Le ATD, Cameron EM, Williams EE, Andrew M, et al. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 2002;21:8442–52.PubMedCrossRef

37.

Hijazi MM, Young PE, Dougherty MK, Bressette DS, Cao TT, Pierce JH, et al. NRG-3 in human breast cancers: activation of multiple erbB family proteins. Int J Oncol 1998;13:1061–7.PubMed

38.

Howard B, Panchal H, McCarthy A, Ashworth A. Identification of the scaramanga gene implicates neuregulin 3 in mammary gland specification. Genes Dev 2005;19:2078–90.PubMedCrossRef

39.

Hayes NV, Newsam RJ, Baines AJ, Gullick WJ. Characterization of the cell membrane-associated products of the neuregulin 4 gene. Oncogene 2008;27:715–20.PubMedCrossRef

40.

Burgess TL, Ross SL, Qian YX, Brankow D, Hu S. Biosynthetic processing of neu differentiation factor. Glycosylation, trafficking, and regulated cleavage from the cell surface. J Biol Chem 1995;270:19188–96.PubMedCrossRef

41.

Campion SR, Niyogi SK. Interaction of epidermal growth factor with its receptor. Prog Nucleic Acid Res Mol Biol 1994;49:353–83.PubMedCrossRef

42.

Thompson SA, Harris A, Hoang D, Ferrer M, Johnson GR. COOH-terminal extended recombinant Amphiregulin with bioactivity comparable with naturally derived growth factor. J Biol Chem 1996;271:17927–31.PubMedCrossRef

43.

Eto K, Eda K, Kanemoto S, Abe SI. The immunoglobulin domain is involved in interaction of neuregulin with ErbB. Biochem Biophys Res Commun 2006;350:263–71.PubMedCrossRef

44.

Wolpowitz D, Mason TBA, Dietrich P, Mendelsohn M, Talmage DA, Role LW. Cysteine-rich domain isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses. Neuron 2000;25:79–91.PubMedCrossRef

45.

Liu X, Hwang H, Cao L, Buckland M, Cunningham A, Chen J, et al. Domain-specific gene disruption reveals critical regulation of neuregulin signalling by its cytoplasmic tail. Proc Natl Acad Sci U S A 1998;95:13024–9.PubMedCrossRef

46.

Bao J, Wolpowitz D, Role LW, Talmage DA. Back signalling by the Nrg-1 intracellular domain. J Cell Biol 2003;161:1133–41.PubMedCrossRef

47.

Golding M, Ruhrberg C, Sandle J, Gullick WJ. Mapping nucleolar and spliceosome localisation sequences of neuregulin 1-beta3. Exp Cell Res 2004;299:110–8.PubMedCrossRef

48.

Yokozeki T, Wakatsuki S, Hatsuzawa K, Black RA, Wada I, Sehara-Fujisawa A. Meltrin b (ADAM19) mediates ectodomain shedding of neuregulin b1 in the Golgi apparatus: fluorescence correlation spectroscopic observation of the dynamics of ectodomain shedding in living cells. Genes Cells 2007;12:329–43.PubMedCrossRef

49.

Marshall C, Blackburn E, Clark M, Humphreys S, Gullick WJ. Neuregulins 1–4 are expressed in the cytoplasm or nuclei of ductal carcinoma (in situ) of the human breast. Breast Cancer Res Treat 2006;96:163–68.PubMedCrossRef

50.

Krane IM, Leder P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 1996;12:1781–8.PubMed

51.

Sartor CI, Zhou CH, Kozlowska E, Guttridge K, Kawata E, Caskey L, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001;21:4265–75.PubMedCrossRef

52.

Breuleux M, Schoumacher F, Rehn D, Kung W, Mueller H, Eppenberger U. Heregulins implicated in cellular functions other than receptor activation. Mol Cancer Res 2006;4:27–37.PubMedCrossRef

53.

Adelaide J, Huang HE, Murati A, Alsop AE, Orsetti B, Mozziconacci MJ, et al. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. Genes Chromosomes Cancer 2003;37:333–45.PubMedCrossRef

54.

Huang HE, Chin SF, Ginestier C, Bardou VJ, Adelaide J, Iyer NG, et al. A recurrent chromosomal breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res 2004;64:6840–4.PubMedCrossRef

55.

Pole JC, Courtay-Cahen C, Garcia MJ, Blood KA, Cooke SL, Alsop AE, et al. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 2006;25:5693–706.PubMedCrossRef

56.

Raj EH, Skinner A, Mahji U, Nirmala KN, Ravichandran K, Shanta V, et al. Neuregulin1-alpha expression in locally advanced breast cancer. Breast 2001;10:41–5.PubMedCrossRef

57.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437–41.PubMedCrossRef

58.

Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumour inhibition by Trastuzumab, and loss of PTEN predicts Trastuzumab resistance in patients. Cancer Cell 2004;6:117–27.PubMedCrossRef

59.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395–402.PubMedCrossRef

60.

Kumar R. ErbB-dependent signalling as a determinant of Trastuzumab resistance. Clin Cancer Res 2007;13:4657–9.PubMedCrossRef

61.

Ritter CA, Perez-Torre M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to Trastuzumab In vivo overexpress Epidermal Growth Factor Receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007;13:4909–19.PubMedCrossRef

62.

de Alava E, Ocana A, Abad M, Montero JC, Esparis-Ogando A, Rodriguez CA, et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007;25:2656–63.PubMedCrossRef

63.

Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453–7.PubMedCrossRef

64.

Park BH, Davidson NE. PI3 kinase activation and response to trastuzumab therapy: what’s neu with herceptin resistance? Cancer Cell 2007;12:297–9.PubMedCrossRef

65.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalling. Science 2007;316:1039–43.PubMedCrossRef

66.

Schelfhout VRJ, Coene ED, Delaey B, Thys S, Page DL, De Potter C. Pathogenesis of Paget’s disease: epidermal heregulin-a, motility factor, and the HER receptor family. J Natl Cancer Inst 2000;92:622–8.PubMedCrossRef

Titel: The Neuregulin Family of Genes and their Multiple Splice Variants in Breast Cancer
verfasst von: Nandini V. L. Hayes
William J. Gullick
Publikationsdatum: 01.06.2008
Verlag: Springer US
Erschienen in: Journal of Mammary Gland Biology and Neoplasia / Ausgabe 2/2008
Print ISSN: 1083-3021
Elektronische ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-008-9078-4

Springer Medizin

The Neuregulin Family of Genes and their Multiple Splice Variants in Breast Cancer

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

The Role of NRG3 in Mammary Development

Role of ErbB4 in Breast Cancer

ErbB4/HER4: Role in Mammary Gland Development, Differentiation and Growth Inhibition

Amphiregulin: Role in Mammary Gland Development and Breast Cancer

HER4 Intracellular Domain (4ICD) Activity in the Developing Mammary Gland and Breast Cancer

The ADAM17–amphiregulin–EGFR Axis in Mammary Development and Cancer

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie